Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617

前列腺癌 医学 转移 肿瘤科 阉割 内科学 前列腺 泌尿科 癌症 激素
作者
Miguel Muniz,Oliver Sartor,Jacob J. Orme,Regina M. Koch,Heide Rosenow,Mahmoud Ahmed,Jack R. Andrews,Adam M. Kase,Irbaz Bin Riaz,Gokce Belge Bilgin,Matthew Thorpe,A. Tuba Kendi,Geoffrey B. Johnson,Praful Ravi,Eugene D. Kwon,Daniel S. Childs
出处
期刊:The Journal of Nuclear Medicine [Society of Nuclear Medicine and Molecular Imaging]
卷期号:: jnumed.124.268277-jnumed.124.268277
标识
DOI:10.2967/jnumed.124.268277
摘要

It is well known that patients with liver metastasis from metastatic castration-resistant prostate cancer have poor or only transient responses to many forms of systemic therapy. Data on outcomes after treatment with [177Lu]Lu-PSMA-617 (LuPSMA) are scarce. The VISION trial reports a hazard ratio for overall survival (OS) in the subgroup of patients with liver metastasis without disclosing the absolute duration of survival. Using real-world clinical data, we examined this important subgroup of patients, describing prostate-specific antigen (PSA) response and OS. Methods: A single-institution database was assembled to include all patients receiving LuPSMA at Mayo Clinic in Rochester, Minnesota, for whom treatment was initiated between March 2022 and March 2023. Baseline clinicopathologic and imaging characteristics were abstracted. Patients were then categorized by presence or absence of liver metastasis on pretreatment prostate-specific membrane antigen (PSMA) PET. PSA response and OS for the 2 groups (liver metastasis vs. no liver metastasis) were compared using χ2 testing and the Kaplan–Meier method, respectively. A multivariate Cox regression analysis was performed, including established prognostic factors. Finally, those with pretreatment circulating tumor DNA as determined in an 83-gene panel were assessed for the presence of pathogenic and likely pathogenic alterations. These findings were summarized using descriptive statistics and compared between the 2 cohorts using the Fisher exact test. Results: The overall cohort consisted of 273 patients, including 43 (15.75%) with liver metastasis on pretreatment PSMA PET/CT. The median number of cycles received was 3 (range, 1–6) for patients with liver metastasis and 5 (range, 1–6) for those without hepatic involvement. The 50% or greater reduction in PSA from baseline response rate was lower for those with liver metastasis than for those without (30.23% [13/43] vs 49.77% [106/213], P = 0.019). At a median follow-up of 10 mo (interquartile range, 9–13 mo), there was a significant difference in median OS (8.35 mo vs. not reached, P < 0.001). On multivariate analysis, the presence of liver metastasis was independently associated with shorter survival (hazard ratio, 4.06; P < 0.001). Conclusion: Our data suggest that the presence of liver metastasis predicts poorer outcomes in patients receiving LuPSMA treatment. Alternative and combination approaches should be explored to maximize the antitumor activity of radiopharmaceutical therapy in the liver.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
homelander完成签到,获得积分10
2秒前
阿六完成签到,获得积分10
2秒前
友好的噜噜完成签到,获得积分10
4秒前
义气萝卜头完成签到 ,获得积分10
5秒前
酷波er的应助被小方采纳,获得10
6秒前
天天快乐的应助被苹果绿采纳,获得10
7秒前
moon发布了新的文献求助10
7秒前
爱笑的夏波完成签到,获得积分20
8秒前
调皮的孤风完成签到 ,获得积分10
9秒前
9秒前
Dafu完成签到,获得积分10
9秒前
10秒前
10秒前
111完成签到 ,获得积分10
12秒前
12秒前
意思完成签到,获得积分10
13秒前
TAO完成签到,获得积分10
13秒前
蟹黄堡完成签到 ,获得积分10
13秒前
13秒前
14秒前
14秒前
15秒前
Desperado完成签到,获得积分10
16秒前
xing_xing给Sapphire的求助进行了留言
17秒前
無名完成签到,获得积分10
17秒前
小方发布了新的文献求助10
18秒前
平凡完成签到,获得积分0
19秒前
AM完成签到,获得积分10
19秒前
20秒前
Ayiiiii完成签到 ,获得积分10
20秒前
沧海一声笑完成签到,获得积分10
21秒前
21秒前
悲伤炒米粉完成签到,获得积分10
22秒前
22秒前
liangjiabin1234完成签到,获得积分10
23秒前
顺利的访琴完成签到,获得积分10
24秒前
林医完成签到,获得积分10
25秒前
靓丽的山蝶完成签到 ,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191093
求助须知:如何正确求助?哪些是违规求助? 9578085
关于积分的说明 21856623
捐赠科研通 7790292
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560326
邀请新用户注册赠送积分活动 2483271